Roche, Genentech End Joust and Agree to Merge

Marino, Jonathan
March 2009
Mergers & Acquisitions Report;3/16/2009, Vol. 22 Issue 11, p8
The article reports on the agreement of Genentech to be acquired by Swiss drugmaker Roche at a sale price of 95 dollars per share in March 2009. It was noted that Roche's bid was first made in July 2008 and it was initially rejected by Genentech's board. The deal values the remaining shares of Genentech which Roche does not already own at 46.8 billion dollars. The companies announced jointly that as a result of the deal, Roche's operations in the U.S. will be moved from Nutley, New Jersey, to Genentech's headquarters in San Francisco, California.


Related Articles

  • Roche, Genentech Finally Agree to Acquisition.  // Bioworld Week;3/16/2009, Vol. 17 Issue 11, p5 

    The article reports on the merging of Basel, Switzerland-based Roche Holdings AG and Genentech Inc. based in South Francisco, California. The merging was closed at the amount of about $46.8 billion. Under the deal, Roche will pay Genentech $95 per share for the remaining 44 percent of stocks...

  • Genentech Ramping Up North County Manufacturing. Chambers, Heather // San Diego Business Journal;8/3/2009, Vol. 30 Issue 31, p1 

    The article reports on the plan of Roche AG to acquire Genentech Inc. in a 47 billion dollars agreement to promote its position in cancer drugs in Oceanside, California in 2009. According to Genentech, approximately 500 workers responsible to produce batches of cancer drug Avastin will keep...

  • Pharma, Biotech Allies Replenish Pipeline. McGee, Patrick // Drug Discovery & Development;Aug2006, Vol. 9 Issue 8, p10 

    The article focuses on the significance of the merger between biotechnology company Genentech Inc. and Roche AG, a pharmaceutical firm, to the field of drug development in the U.S. The history of Genentech and how it was consolidated with Roche is discussed. Moreover, because of the risk of...

  • Roche $43.7B Genentech Offer Likely to Feel Upward Pressure. Young, Donna // BioWorld International;7/23/2008, Vol. 13 Issue 30, p3 

    The article reports that Roche Holding AG has offered $43.7 billion to purchase the 44 percent it does not own already of Genentech Inc. If the merger is completed, Roche would gain worldwide control of Avastin, which Genentech markets in the U.S., and other cancer drugs like Herceptin and...

  • Goodbye Genentech, But No Obit for Biotech Yet, Please. Boggs, Jennifer // BioWorld Today;3/16/2009, Vol. 20 Issue 49, p1 

    The article focuses on the possible impact of the merger between Roche Holdings AG and Genentech Inc. on the biotechnology industry. In the said deal, Roche agreed to acquire the remaining shares of Genentech priced at $95 per share. Some speculate that the merger could have a large impact on...

  • Roche launches hostile bid for Genentech shares.  // Nature;2/5/2009, Vol. 457 Issue 7230, p648 

    The article discusses the hostile bid by the Swiss pharmaceutical company Roche to capture a larger percentage of the U.S. biotechnology company Genentech than it already owns. Roche's request was initially denied by Genentech who claimed that the offer was too low. Topics include how the global...

  • Genentech Again Nixes Roche Takeover Offer.  // BioWorld Today;2/24/2009, Vol. 20 Issue 35, p3 

    The article reports on the decision of a special Genentech Inc. board committee to reject a takeover offer from Roche Holdings AG. The committee recommended against accepting Roche's hostile $44 billion buyout offer, citing Genentech's strong projected financial performance, among other reasons....

  • Roche exercises its option, buys balance of Genentech.  // Medical Marketing & Media;Jul99, Vol. 34 Issue 7, p8 

    Reports on the decision of Roche Holding to acquire the balance of drug firm, Genentech Inc.

  • Mergers & Acquisitions Update: Genentech considers Roche's proposal as undervaluing the company.  // PharmaWatch: Biotechnology;Oct2008, Vol. 7 Issue 10, p16 

    The article reports that Genentech Inc. has unanimously concluded that the proposal of Roche to acquire the shares of Genentech for $89 per share substantially undervalues the company in the U.S. It is noted that the special committee does not support the proposal but would consider a proposal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics